Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,721.47
(
0.33%
)
US TECH 100
24,149.60
(
0.56%
)
Dow Jones
47,045.56
(
0.21%
)
Brent Oil
100.26
(
1.99%
)
Bitcoin
74,404.98
(
-0.59%
)
News Focus
News Focus
Post# of 257251
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122790
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 118752

Saturday, 04/23/2011 6:07:11 PM

Saturday, April 23, 2011 6:07:11 PM

Post# of 257251
ABT’s 44% YoY growth in ex-US sales of drug-eluting stents (#msg-62371726) is an impressive stat insofar the growth was entirely organic. Rapid uptake of Xience in Japan was a major contributor.

ABT’s DES sales in 1Q11 include Xience, Xience Prime, and the profit share ABT gets from BSX on Promus (which has now ended).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now